|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.59 USD | -0.87% |
|
-7.40% | -8.14% |
| 14/01 | BioMarin Pharmaceuticals Aims for Sustained Growth in 2026, Wedbush Says | MT |
| 13/01 | BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down | MT |
Evolution of the Average Target: BioMarin Pharmaceutical Inc.
Evolution of the Target Price: BioMarin Pharmaceutical Inc.
Changes in Analyst Recommendations: BioMarin Pharmaceutical Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +63.11% | |||||
| +11.34% | |||||
| +14.47% | |||||
| +3.19% | |||||
| +33.04% | |||||
| +13.33% | |||||
| -2.72% | |||||
| +25.77% | |||||
| +10.95% | |||||
| -6.63% | |||||
| Average | +16.58% | |||||
| Weighted average by Cap. | +14.85% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Truist Securities | |
| Leerink Partners | |
| Stifel Nicolaus | |
| RBC Capital Markets | |
| Morgan Stanley | |
| HC Wainwright | |
| UBS | |
| Oppenheimer | |
| BofA Securities | |
| Wolfe Research | |
| William Blair & Co. | |
| Baird | |
| Scotiabank | |
| Wells Fargo Securities | |
| Wedbush | |
| BMO Capital | |
| Barclays | |
| Cantor Fitzgerald | |
| Bernstein | |
| Canaccord Genuity | |
| Citigroup | |
| Piper Sandler | |
| Guggenheim | |
| Credit Suisse | |
| SVB Securities LLC | |
| Jefferies & Co. | |
| JPMorgan Chase | |
| Goldman Sachs | |
| SVB Leerink | |
| Evercore ISI |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMRN Stock
- Consensus BioMarin Pharmaceutical Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition